2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol manufacturers
- Sergliflozin A
-
- $112.00
-
2026-07-27
- CAS:360775-96-8
- Purity: 99.71%
- Supply Ability: 10g
|
| | 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol Basic information |
| | 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol Chemical Properties |
| Melting point | 94.8-95.5 °C | | Boiling point | 590.7±50.0 °C(Predicted) | | density | 1.344±0.06 g/cm3(Predicted) | | solubility | Acetonitrile: Slightly Soluble: 0.1-1 mg/ml
DMSO: Sparingly Soluble: 1-10 mg/ml | | pka | 12.82±0.70(Predicted) |
| | 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol Usage And Synthesis |
| Uses | Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect. | | References | [1] Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and…
[2] KENJI KATSUNO. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 320 1: 323-330. DOI: 10.1124/jpet.106.110296 |
| | 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol Preparation Products And Raw materials |
|